ESR1 and breast cancer: The ER downregulation we observed with fulvestrant at 6 weeks is consistent with previous short‐term (<3 weeks) pre‐surgical primary breast cancer studies for short‐acting (6 or 18 mg/daily subcutaneously28) and long‐acting formulations (50–250 mg/month intramuscularly7).